Alzheimer's disease (AD) treatment and its derivative ZT-1

[Guest guest]

Hi Alon,

 

 

>> Alzheimer's disease (AD) treatment and its derivative ZT-1

 

> anyone knows what zt-1 is Alon

I had not time to read up on that, but I understand that ZT-1 is a

coommercial implant used in Alzheimer's. See: http://tinyurl.com/2uek5v

 

Best regards,

 

[Guest guest]

In a message dated 7/31/2007 3:10:58 A.M. Eastern Daylight Time,

writes:

 

Hi Alon,

 

>> Alzheimer's disease (AD) treatment and its derivative ZT-1

 

> anyone knows what zt-1 is Alon

I had not time to read up on that, but I understand that ZT-1 is a

coommercial implant used in Alzheimer's. See: _http://tinyurl.http://tin_

(http://tinyurl.com/2uek5v)

 

Best regards,

 

 

 

 

 

 

It looks like they are using Huperzine A which is a derivitive of club

moss to slow down the enzyme acetylcholinesterase so there will be more of

the neurotransmitter acetylcholine to stimulate nuerons.

 

Chris

 

Huperzine A is discussed in Mind Boosters, a book by Ray Sahelian, M.D.

 

Huperzine A is an extract from a club moss (Huperzia serrata) that has been

used for centuries in Chinese folk medicine. Huperzine's action has been

attributed to its ability to strongly inhibit acetylcholinesterase, the enzyme

that breaks down acetylcholine in the synaptic cleft. Acetylcholine is involved

in memory and learning. By inhibiting the enzyme that breaks it down, more

acetylcholine becomes available to stimulate neurons. _Alzheimer’s_

(http://www.raysahelian.com/alzheimer.html) disease is a condition where

there’s a

relative shortage of acetylcholine.

Several studies have been done over the past few years with huperzine A both

in China and the United States. These studies have shown that Huperzine A is

many times more effective and selective than tacrine (a

cholinesterase-inhibiting pharmaceutical drug) in inhibiting cholinesterase

(Cheng 1996).

Huperzine A has also been found to be beneficial in patients with Alzheimer’s

disease. Scientists at Zhejiang Medical University, in Hangzhou, China

administered

200 mcg of huperzine A to fifty patients with Alzheimer’s disease for a

period of eight weeks and compared the results to a group who received placebo

pills (Xu 1995). The study was done in a double blind, placebo controlled and

randomized manner. The results showed 58 percent of the patients treated with

huperzine A had improvements in memory, cognition, and behavioral functions

whereas only 36 percent of those on placebo improved. No severe side effects

were found. Blood pressure, heart rate, electrocardiogram,

electroencephalogram, liver and urine tests did not show any major

abnormalities. The

researchers say, " Huperzine A is a promising drug for symptomatic treatment of

Alzheimer's disease. "

 

 

 

 

************************************** Get a sneak peek of the all-new AOL at

http://discover.aol.com/memed/aolcom30tour